339 related articles for article (PubMed ID: 19676041)
1. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
[TBL] [Abstract][Full Text] [Related]
2. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
6. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
10. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
11. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
[TBL] [Abstract][Full Text] [Related]
12. Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
Xu J; Yang W; Wang Q; Zhang Q; Li X; Lin X; Liu X; Qin Y
Int J Clin Exp Pathol; 2014; 7(11):7915-22. PubMed ID: 25550832
[TBL] [Abstract][Full Text] [Related]
13. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
14. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
15. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
16. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
17. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
19. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
